Tau PET imaging in cognitively normal elderly subjects: A twin approach - Tau Twin

Amsterdam UMC VUmc0 sites80 target enrollmentDecember 19, 2018

Overview

No summary available.

Registry

who.int

Start Date

December 19, 2018

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

Amsterdam UMC VUmc

•Inclusion in PreclinAD study (2014\.210\) and a subject must be older than 60 years and have received an \[18F]flutemetamol amyloid PET scan and/or have a known amyloid status obtained from CSF.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 10
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range 70

•1\.Has contra indications for MRI scanning and therefore has not received brain MRI;
•2\.Has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with interpretation of PET scan;
•4\.Has a relevant history of severe drug allergy or hypersensitivity. Relevant severe drug allergies should be determined by the Principal Investigator or Co\-Principal Investigator, and any questions about a subject’s eligibility can be directed to Avid Radiopharmaceuticals Inc.;
•5\.Has ever participated in an experimental study with a tau agent, unless it can be documented that the subject received only placebo during the course of the trial;
•6\.Has been injected with a previously administered radiopharmaceutical within 6 terminal half\-lives or when total yearly radiation exposure exceeds 16\.1 mSv for female and 22\.4 mSv for male participants\[25].
•7\.Has a history of severe traumatic brain injury (TBI).